Due to the impact of insulin resistance on the pathophysiology of MASLD, potential pharmacologic treatments for MASLD have focused on hypoglycemic agents, including metformin, SGLT2-I, PPAR agonists, GLP-1 receptor agonists, and multi-agonists [39]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.